Back in 2021, a Special Purpose Acquisition Company (SPAC) ran from $10 to $60 nearly overnight.
The ticker was CCIV, and the rumor was they were going to bring Lucid Motors to the market. I made the call to get bearish into the news as the SPAC vehicle had moved entirely too fast, and any definitive agreement would cap the upside on the stock.
Here’s what happened:
The SPAC mania left many investors with a hangover and a drawdown of 80%...
But hey, at least the companies got funding.
Over the past few years, these SPAC names have deflated, and others have fallen apart due to busted deals.
But I’ve found one that appears to have all the bad news priced in – plus an incredible product that insiders believe in.
I’m a man, which means I’m at low risk for breast cancer.
It also means I don’t get mammograms… but from what I hear, it’s not the most comfortable process in the world. The technician squeezes the breast tissue so they can shoot X-rays through cells to find any evidence of breast cancer.
The wild part is that 10-15% of all mammograms have false positives. That means the doctor will call you back for additional tests, leaving the patient wracked with worry that they’re going to have a full-blown cancer diagnosis.
It’s no wonder more than 40% of women report serious anxiety about getting this screening…
But one company is changing that.
They’ve developed an ultrasound device that can take a 3D image of the breast tissue. The patient simply lies down into a warm water bath and lets the machine do the work.
No uncomfortable squeezing, no radiation… and less patient anxiety and improved false positive rates. It seems like a great invention – so why has the stock been killed?
In SPAC land, you’re going to have the sponsor that fills a shell company with cash, and then does a reverse merger to bring the company to market. Some SPACs do well, others are busts, and others are raging dumpster fires.
In this case, the sponsor lit the match.
In September 2023, it filed a lawsuit against the imaging company, claiming they violated the merger agreement. They claim the company was engaging with other suitors, violating their exclusivity clause.
The lawsuit was dropped, but that’s not a good look as the company gets ready to complete a reverse merger.
When the merger was announced in 2022, there was an expectation that the company would pull in $41 million in cash from the sponsor, which assumed no redemptions. Then the minimum cash condition was removed.
I can’t prove it 100%, but I think the sponsor just dumped shares onto the market, sending the price from $10 to under $1 in very short order.
It appears the company raised under $6 million instead of a much higher amount needed:
So we have a company with a great product, but a terrible stock structure that’s bleeding cash and still has some regulatory hurdles to clear. So why the heck are we looking at this name?
In November 2024, the company hada private placement funding round. The total amount was about $2.6 million, and it was ALL from insiders.
The chairman of the board put down $1.8 million, and two directors put in $300k combined. This is a huge signal.
Now couple that with the same chairman buying $1.6 million in March 2025, followed quickly by another $250k buy. The CEO also picked up $250k worth.
Many of these positions are a combination of equity and warrants. Warrants are kind of like call options, where you have the right to buy at a given strike price – this time at $0.67.
This makes the stock a great “option-like” setup, where it’s either going to dilute itself into dust, or the product is solid enough to give distressed equity investors the chance at earnings multiples of their capital.
I’ve already sent the full trade alert to my members. I believe the FDA approval process will be what makes or breaks the stock… and if the new FDA admin is more accommodative to new treatments, this name has a shot at serious upside.
If you’d like to learn more about how we’ve followed similar setups from company insiders to stock moves of 115% in 60 days, 90% in 24 days, and 88% in seven days…
And option gains of 443%, 520%, and an astounding 1,091% – all in a matter of a few days to a few weeks – click right here to view a free training video where I’ll walk you through it and give you details of three more insider opportunities we’re tracking right now.
For years, the story has been about tech stagnation.
Big platforms got bloated. Crypto was stuck in the penalty box. Wall Street flirted with disruption but never quite sealed the deal.
But suddenly… almost quietly… we’re seeing signs that the engine is turning over again.
And it’s not just one thing. It’s a convergence.
Make no mistake: The next tech supercycle isn’t coming – it’s already here.
Here’s what we’re watching.
While everyone was distracted by GPT-4 and chatbots that can write your emails, Google quietly dropped its next-gen large language model: DolphinGemma.
This isn’t just another “AI does X” headline. This LLM is specifically fine-tuned to decipher dolphin language.
That’s right: Google is throwing compute and brainpower behind decoding an entirely different species’ communication system. It’s like the opening scene of a sci-fi movie…
Except it’s real, and it’s happening right now.
I told y’all it was only gonna get weirder from here…
Evo 2 is a “genomic foundation AI model” that interprets the language of the human genome.
By analyzing genetic sequences, Evo 2 is helping scientists pinpoint drivers of diseases like cancer, potentially accelerating the pace of drug discovery far beyond what traditional methods allow.
The model’s capabilities suggest we may be on the brink of major biotech breakthroughs – quicker and more precise than the markets currently anticipate.
While the AI crowd races for compute supremacy, another shift is happening on the financial front.
After years of friction, crypto and traditional finance are finally starting to converge. Not just in theory – in practice.
Major exchanges are linking up with legacy financial institutions. Regulatory clarity is emerging. And tokenized assets are beginning to resemble traditional securities, on-chain.
It’s not about meme coins anymore. It’s about market structure.
Just look at what’s happening with Coinbase.
Coinbase isn’t just surviving the regulatory onslaught. It’s becoming the default U.S. crypto infrastructure provider.
It’s powering ETFs. It’s securing custody deals. And it’s positioning itself as the compliant bridge between decentralized finance and the institutional world.
That’s not a fad… that’s a moat.
And it’s exactly the kind of shift that re-rates a company from speculative asset to core holding.
Then there’s Bakkt (BKKT). If Coinbase is the loud front-runner, Bakkt is the quiet technician.
It’s been quietly signing white-label crypto deals with enterprise partners. Building out payment rails. And positioning itself as a middleware layer between big institutions and digital assets.
If crypto is finally getting invited into the TradFi boardroom, BKKT maybe holding the keys.
So… what now?
This all paints a very clear picture: We’re witnessing a new tech regime emerge.
And in every shift, there are a handful of companies that break away from the pack early.
The challenge, of course, is figuring out who they are before the crowd catches on.
I recently recorded a live training session to show our number-one strategy for spotting these opportunities early…
Before the breakout moves.
It’s a strategy that’s signaled moves of 275% in seven days… 728% in four months… 1,062% in less than 30 days…
And even 1,366% in a matter of weeks.
Click here to watch the live replay now – because the future doesn’t announce itself.
It just shows up… and rewards the people who were paying attention.
If you want to understand what’s happening in the global tariff chess match, you don’t need a crystal ball.
You need a copy of The Art of the Deal.
Because what we’re seeing isn’t traditional policy – it’s classic negotiation theater, straight from Trump’s 1987 playbook. And whether you love him or loathe him, understanding his strategy gives you a lens to interpret what’s actually happening behind the headlines.
In The Art of the Deal, Trump lays out his signature style: anchor the conversation with something extreme, escalate tension to gain leverage, control the narrative, and then walk back just enough to make a deal feel like a win for everyone…
Most of all him.
That’s what we’re watching now.
First came the broad threats: 10% across the board tariffs.
Then the walk-back: selective tariffs on a case-by-case basis.
Then the escalation: 125% tariffs on China.
Now the real game: 130+ countries negotiating individually with the U.S., desperate to cut their own side deals.
The point isn’t the tariffs. It’s the leverage.
This is about isolating China, forcing global compliance, and establishing a new trade regime with the U.S. at the center.
To get there, though, the process needs to feel chaotic. Uncertain. Unstable.
Why? Because that’s how you create leverage.
Here are just a few tactics from Trump’s negotiation arsenal now playing out in real time:
If you’re looking for certainty in this, I hate to be the one to break it to you: We’re not going to get it.
Markets are trying to price in something that doesn’t have a clean resolution. It’s not clear when a deal will happen… or what a “deal” even looks like.
There are no rules, no roadmap. Just one guy with the microphone and a copy of his own book.
But that doesn’t mean we’re flying blind.
While investors chase headlines and try to interpret cryptic tweets, corporate boardrooms are doing something else entirely: Assessing real risk and real opportunity.
They’re asking:
And when they decide they’ve got clarity, they act. Quietly. Through insider buying.
Because insiders don’t guess. They know when their business is about to benefit – and they put money behind it.
That’s why we’ve been watching insider transactions as the most reliable signal for what comes next. Not what people say…
But what they do with their own capital.
Want to see what they’re telling us?
I recently hosted a live session exploring how insider buying can reveal which stocks might rise from the ashes of this tariff turbulence – who the next winners and losers might be in this brand-new regime.
I encourage you to watch the recording right here… because while no one knows exactly what this market will do next, the people inside the boardrooms just might.
After Trump’s “Liberation Day” where he announced new tariffs on practically every nation in the world, stocks plummeted…
And if you’ve been watching the headlines, you probably think the market crash is 100% caused by the tariffs.
But the truth is, this selloff has nothing to do with tariffs anymore.
Here’s what’s really going on, what it means for the economy, and where the smart money is heading next.
Now, it’s true that when tariffs were announced, the market responded.
But the next leg down? It’s margin calls.
Too many investors got over their skis, ignored the risk, and now they’re being forced to liquidate. This is what happens when people don’t hedge ahead of the most obvious risk event since the 2011 fiscal cliff.
The result? A cascading selloff, and a spike in volatility. For disciplined inventors, that’s not something to fear – it’s an opportunity.
Whether you’re pro or anti-tariff, there are legitimate concerns behind the current policy.
Former U.S. Trade Representative Bob LIghthizer recently laid them out: from power grid infrastructure to shipbuilding to semiconductors, the U.S. is dangerously dependent on nations that don’t play fair.
One key example: the U.S. cannot currently manufacture its own large-scale electrical transformers. There’s no Strategic Petroleum Reserve equivalent for the grid – and if even one of the 10 major U.S. substations went down in a cyberattack, recovery would take months, maybe longer.
We also can’t ignore the realities of forced labor. Look at a country’s export volume relative to average wages. If a nation exports $10B but average per capita income is $500, that’s not productivity, it’s exploitation. Slavery is a feature, not a bug, of centrally controlled economies like China and Vietnam.
As equity markets break down, the effects will bleed into credit markets. That’s when the Fed gets off the sidelines. A liquidity crisis in equities will pressure credit and give the Fed the air cover it needs to pivot.
Meanwhile, tariff revenues give the Treasury a new lever – offsetting spending with income instead of debt. Add in government efficiency mandates and defense spending cuts, and this isn’t just trade policy. It’s monetary policy in disguise.
But make no mistake: no one knows exactly how this plays out.
The last time we saw this kind of global trade disruption, we were on the gold standard. The world has changed. The U.S. now controls the reserve currency, and the political will is shifting toward self-sufficiency.
This means opportunity… but only if you know where to look.
There’s a renaissance brewing in U.S. manufacturing. Today’s smartest founders aren’t launching another SaaS app. They’re building robotics firms, defense tech, and precision manufacturing plants.
And the talent is there. Boom Supersonic built a new supersonic jet in a decade… from scratch. What’s been missing isn’t skill; it’s political will. That’s changing.
As energy demand rises, kilowatt-hour consumption will spike. Mining, refining, rare earths – all back in play. The companies nobody cared about since 2007 are suddenly vital again.
Industrials. Nuclear. Domestic production. Defense. These are the sectors where alpha lives now.
When headlines scream panic, corporate insiders often begin quietly buying their own stock…
Because they know how these shifts can reshape their industries over the next three to five years.
These are the people with skin in the game. The ones who see the road ahead, not just the road behind.
I’ve put together a free training that exposes the legal mechanism these insiders use to make fortunes in the stock market – and how you can follow their moves for the shot at massive gains…
Click right here to watch it at no cost.
After Trump’s “Liberation Day” where he announced new tariffs on practically every nation in the world, stocks plummeted…
And if you’ve been watching the headlines, you probably think the market crash is 100% caused by the tariffs.
But the truth is, this selloff has nothing to do with tariffs anymore.
Here’s what’s really going on, what it means for the economy, and where the smart money is heading next.
Now, it’s true that when tariffs were announced, the market responded.
But the next leg down? It’s margin calls.
Too many investors got over their skis, ignored the risk, and now they’re being forced to liquidate. This is what happens when people don’t hedge ahead of the most obvious risk event since the 2011 fiscal cliff.
The result? A cascading selloff, and a spike in volatility. For disciplined inventors, that’s not something to fear – it’s an opportunity.
Whether you’re pro or anti-tariff, there are legitimate concerns behind the current policy.
Former U.S. Trade Representative Bob LIghthizer recently laid them out: from power grid infrastructure to shipbuilding to semiconductors, the U.S. is dangerously dependent on nations that don’t play fair.
One key example: the U.S. cannot currently manufacture its own large-scale electrical transformers. There’s no Strategic Petroleum Reserve equivalent for the grid – and if even one of the 10 major U.S. substations went down in a cyberattack, recovery would take months, maybe longer.
We also can’t ignore the realities of forced labor. Look at a country’s export volume relative to average wages. If a nation exports $10B but average per capita income is $500, that’s not productivity, it’s exploitation. Slavery is a feature, not a bug, of centrally controlled economies like China and Vietnam.
As equity markets break down, the effects will bleed into credit markets. That’s when the Fed gets off the sidelines. A liquidity crisis in equities will pressure credit and give the Fed the air cover it needs to pivot.
Meanwhile, tariff revenues give the Treasury a new lever – offsetting spending with income instead of debt. Add in government efficiency mandates and defense spending cuts, and this isn’t just trade policy. It’s monetary policy in disguise.
But make no mistake: no one knows exactly how this plays out.
The last time we saw this kind of global trade disruption, we were on the gold standard. The world has changed. The U.S. now controls the reserve currency, and the political will is shifting toward self-sufficiency.
This means opportunity… but only if you know where to look.
There’s a renaissance brewing in U.S. manufacturing. Today’s smartest founders aren’t launching another SaaS app. They’re building robotics firms, defense tech, and precision manufacturing plants.
And the talent is there. Boom Supersonic built a new supersonic jet in a decade… from scratch. What’s been missing isn’t skill; it’s political will. That’s changing.
As energy demand rises, kilowatt-hour consumption will spike. Mining, refining, rare earths – all back in play. The companies nobody cared about since 2007 are suddenly vital again.
Industrials. Nuclear. Domestic production. Defense. These are the sectors where alpha lives now.
When headlines scream panic, corporate insiders often begin quietly buying their own stock…
Because they know how these shifts can reshape their industries over the next three to five years.
These are the people with skin in the game. The ones who see the road ahead, not just the road behind.
I’ve put together a free training that exposes the legal mechanism these insiders use to make fortunes in the stock market – and how you can follow their moves for the shot at massive gains…
Click right here to watch it at no cost.
It was late August 2015. I was sitting in the parking lot of my local Chinese buffet.
The S&P 500 saw its hardest 3-day selloff in years on news of a Chinese currency intervention.
The “Chinese Buffet Trade” is a tradition that’s worked for every major stock market bottom. From 2011 to 2018, when the markets were in a panic, I would load up on call options, then stuff my face with some chicken lo mein.
In August 2015, there was no liquidity in the futures markets. Janet Yellen was giving a press conference, and she had a coughing fit to the point that she had to pause remarks.
Equity futures tanked. From a cough.
When volatility picks up, investors start obsessing about Fed policy to “save” the markets. And if the market doesn’t get what it wants…
… we see a Tantrum.
Right now, the markets are in the early stages of a tantrum. The AI hyperscale trade is wearing off and there’s no narrative to attach to price action.
Even though the Nasdaq was hitting all time highs, there’s hidden weakness:
Semiconductors haven’t been in a bull market since the summer of 2024.
The Nasdaq keeps experiencing “rug pulls” and higher volatility.
And bitcoin cracked 90k, leaving the crypto market with 6 months of bagholders.
SO FAR, this is a “normal” pullback.
Yet I’m starting to see signs of the Tantrum Playbook.
The Tantrum starts as a slow burn. Nothing is “bad” in the markets, but you just don’t see the same kind of push higher on the market’s bellwether stocks, like NVDA.
Then the Tantrum has a Volatility Pivot. It’s usually a combination of a catalyst and some offsides positioning in the options market.
Like when the S&P 500 had a -4 standard deviation move back in December:
If the market bounces but can’t find sustained buyers, then market deterioration drastically increases the odds of a Tantrum. Selling picks up, and the large cap tech stocks that have buoyed the market simply stop working.
And there’s ZERO introspection from market participants.
Fund managers aren’t going to say, “maybe I shouldn't have bought the market at a 37 multiple.”
What do they do? They blame the Fed! And then you get headlines like this:
At some point, the Tantrum becomes the primary Narrative that drives markets. We saw this play out during the “Taper Tantrum” of 2016:
And the Tech Wreck of 2018:
The Fed will claim they are above the fray in the stock market.
Yet at some point, equity volatility bleeds over into bonds and credit. That’s when the Fed is forced to make a pivot.
The Tantrum halts, the market gets some milk and cookies, and we fly higher.
Consensus is that the Fed has its back against a wall. They can’t cut rates because inflation is sticky, but if surprise deflation shows up they could be committing a policy error by not acting soon enough.
There’s one policy tool that could be just enough to stop a Stock Market Tantrum without overshooting on a rates decision.
The Fed’s been running a Quantitative Tightening (QT) program for a few years now.
They own a bunch of US Treasuries. When those USTs mature, the Fed can roll that capital back into another round, or they can choose not to reinvest— which is QT.
This is the lever. But of course they can’t give us a straight answer:
In an interview on Wednesday with Yahoo Finance, Atlanta Fed President Raphael Bostic said the Fed may be nearing levels where it can stop QT but added "there's not precision on that."
"I think it's going to be appropriate for us to be more cautious today and moving forward than we have been in the past six or eight months" as this process plays out, he said.
They’re trying to tell us they have a pacifier, but won’t give it up unless the market starts to whine.
It’s not wise to trade strictly off Fed policy, yet there are some investing themes you should start following if you aren’t already.
If the Fed bails on QT, that means they’re now a buyer back in the UST market. That could help keep rates (and the dollar) pushed down even if we see more inflationary pressures.
So while the majority of the market is obsessed on finding a bottom in Large Cap Tech, the better plays are going to be in underinvested areas like commodity stocks and emerging markets.
This is a market-cap weighted view of the S&P 500. See those two boxes in the lower right corner? That’s all the energy and materials stocks in the S&P 500.
These sectors, as a whole, have a lower valuation than AAPL or NVDA.
Yet they offer exceptional risk reward, and a good place to park dollars in a volatile market.
Here’s an example in Compass Minerals (CMP):
The stock has been left for dead in a 4 year bear market. The dividend was eliminated and has been in a trading range for 9 months. If it can manage to hold above 13.50, then you’ve got the chance for a solid trending stock.
Lycos. Altavista. AskJeeves. Dogpile.
These were the early search engines, back when we still called it the “World Wide Web.”
It was incredibly competitive and cutthroat, and it was a few years before Google rose to domination.
Right now, the AI space is giving off the same vibes.
Grok3 was released recently, and it’s quite good. OpenAI is rattling the sabers with GPT-5, and the rest of the AI ecosystem is accelerating to capture market share.
These are all “Large Language Models,” or LLMs. They hoover up as much text and code they can find, apply some weights, and give the end user the most likely combination of words for the prompt that was provided.
All in English.
Yet there’s a new AI out there that’s working off a different language. One where there’s only 4 letters.
Stripe is a payments company that was bootstrapped by the Collison brothers, and is now sporting a valuation around $85 billion.
Patrick Collison took some of that cash and helped co-found the Arc institute, a biomedical research org that works with Stanford, UC Berkeley, and UCSF.
Last week, they released Evo-2, a Large Genetic Model (LGM).
Arc took the genomic sequencing from over 100,000 different species and threw it into their model.
Only four letters - A, T, C, G. The building blocks of life.
It’s incredible what they’ve been able to do with it.
For example, the model only has a single human genome in the model, yet it can predict how the BRCA gene mutation could lead to human breast cancer.
We now have the possibility of bespoke genetic therapies, novel drug discovery, and epigenetic research. Which is all incredible, world changing technology. But that’s not why I’m excited.
It can create new genetic sequences from scratch. We’re talking full blown synthetic biology.
Do you know what that means?
WE’RE BRINGING BACK DINOSAURS
JURASSIC PARK IS GOING TO BECOME REAL
And the best part? The entire project is open source. Not just the model, but the training data and the weights that they used.
Anyone can use this technology. Including publicly traded biotech firms.
Faster and cheaper. That’s what a disruptive technology like Evo-2 can do to the biotech space.
And it’s not priced into the markets. There’s a massive edge.
Here’s how the “traditional” model works for biotech investing:
The model doesn’t work anymore. Financial speculators don’t have to wait for FDA results to see the efficacy of a treatment— they can plug it into an applied healthcare AI to see if the mechanism is going to work.
This holds doubly true for any companies working in immunotherapy or genetic treatments.
Expect biotech stocks to see more volatility and trend before FDA events even hit, because information arbitrage is going to collapse, and this causes large price moves.
A few drugs in a pipeline is not going to be a viable model going forward. The value proposition in biotech is now about the ability to have a “launchpad” to quickly discover and develop new drugs.
Below are two companies we’ve recently recommended to clients. We’ve already scaled out of some profits, yet I think the upside could persist based on my thesis.
This isn’t a biotech company— it’s an AI company with a biotech arm. They have Recursion OS, that integrates live experiments, computational biology, and machine learning to screen and develop drugs.
They’re not trying to hit the lotto on a single drug. Instead, they’re going through thousands of potential drug candidates and finding the treatments with the highest efficacy to get through FDA trials.
They can move fast, use less cash, and get more drugs to market than a traditional model.
A slightly different model than Recursion— they use a “hub and spoke” model where they have centralized key parts of the business, then spin out smaller companies that target a specific therapeutic.
Any company that puts this in their pitch deck is worth a look:
They’ve got some FDA approvals under their belt, and it appears they’ve got a good flywheel of drug discovery and development so you don’t have to worry about the dilution trap seen in biotech so often.
What happens when BBIO adds a genomic research AI assistant? How much upside is not priced in?
As a group, biotech has sucked for years. XBI has been stuck in a trading range for well over a year.
High interest rates don’t help… money isn’t cheap, and neither is funding trials.
There’s also the FDA and the uncertainty around the new regulatory environment.
These are “rear view mirror” risks. In the future, healthcare AI models are going to give investors a predictive ability as to what therapeutics will have the best outcomes before the trials complete.
Plus, our Early Warning Signal will help tip us off to where some of the best-informed investors on the planet are directing their capital in this exciting new space…
Click here to see how we’ve followed this signal to opportunities as high as 1,000%+.
Just a few months back, I posted this blog about our latest target in the precious metals space.
The company was Dakota Gold, ticker DC.
Now, I admittedly don’t know much about the gold industry. I’m not a professional assayer.
But when the Vice President of Exploration suddenly buys $50,000 of his company’s stock, I pay attention.
So… how did I know he was buying up that amount of stock in the first place?
Check it out:
This is called a Form 4.
Corporate executives have to fill one of these out within 48 hours of buying or selling their stock.
Our man James here made two purchases last June totaling $50k…
A high-conviction bet on a stock that was underperforming to say the least:
Again: he made those purchases in June…
And in early February, the company issued this press release:
The stock popped nearly 30% on the news…
And our members are up over 40% since we entered the trade in August.
That works out to somewhere near a 90% annualized return…
All thanks to our guy on the inside.
Here’s the deal…
Corporate insiders like James do this kind of thing ALL. THE. TIME.
There are literally thousands of Form 4s filed every day…
But not all of them represent a real opportunity.
To find the real gems, you have to know which ones to toss aside…
So you can uncover opportunities like Five Below that popped 384%...
CRMT that ran 483%...
NMI Holdings that soared 506%...
ZEBRA Technologies that surged 1,105%...
And APPS that gained an incredible 2,334%.
We’ve put together a free training that explains everything you need to know – where to find these Form 4s, how to separate the wheat from the chaff…
And the little-known SEC “loophole” that makes it all completely legal.
